In today’s briefing:
- Personalis Has Already Doubled—Is Merck About To Trigger Another Surge?
- Australia: Relative Value Opportunities and Pair Trades (21 July 2026)
- Ascentage Pharma (6855 HK): ADS Offering Justified, 2027 Likely To Be An Inflection Point
- IPO Rating: Scribe Therapeutics, Inc.
- Scribe Therapeutics Inc. (SCTX): Small Cap CRISPR Biotech Sets Terms Seeking $100m Raise
- Apnimed Inc. (APMD): Peeking at the IPO Prospectus of a Sleep-Related Biopharma
- LC Capital Extends PC Partner Position; Rich Placement
- Bears Build Into Earnings Season: Short Interest Spikes Across Small Caps
- Scribe Therapeutics (SCTX) Targets $100 Million IPO
Personalis Has Already Doubled—Is Merck About To Trigger Another Surge?
- Personalis has become one of the market’s most closely watched precision-oncology stocks after reports indicated that the company is evaluating a potential sale following takeover interest from Merck and two other bidders.
- The timing is striking.
- Personalis shares had already risen nearly 100% in 2026 before the report surfaced, lifting its market capitalization to roughly $1.6 billion and raising a difficult question for investors: how much takeover upside may still remain after such a sharp rally?
Australia: Relative Value Opportunities and Pair Trades (21 July 2026)
- Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.
- Highlights: In Australia, currently four pair trade opportunities persist across three sectors.
- Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.
Ascentage Pharma (6855 HK): ADS Offering Justified, 2027 Likely To Be An Inflection Point
- Ascentage Pharma (6855 HK) has filed for a likely future at-the-market equity offering program of American depositary shares to raise up to US$ 200M.
- Company reported revenue of RMB 574.1M in 2025, down 41.5%, largely because of high base effect. Revenue from Olverembatinib was up 81% YoY. Lisaftoclax garnered RMB 70.6M in sales.
- Losses will continue and R&D expenses, commercialization cost will be catered to by the likes of above ADS offering and previous placement proceeds. 2027 likely to be an inflection point.
IPO Rating: Scribe Therapeutics, Inc.
- Scribe Therapeutics is expected to list on the Nasdaq under the ticker SCTX, offering approximately 7.15 million shares at a price range of $13.00 to $15.00 per share, targeting approximately $100 million in gross proceeds.
- The company is developing next-generation CRISPR-based genetic medicines designed to improve the precision, specificity, and safety of gene editing therapies.
- Its lead programs focus on cardiovascular and metabolic diseases, representing some of the largest potential markets within genomic medicine.
Scribe Therapeutics Inc. (SCTX): Small Cap CRISPR Biotech Sets Terms Seeking $100m Raise
- Scribe Therapeutics is set to revive biotech IPO activity with a CRISPR-focused offering backed by strategic investors Eli Lilly and Sanofi.
- The clinical-stage biotech’s lead candidate, STX-1150, remains early with Phase 1 data expected in 1H27, requiring investor patience.
- Scribe’s CRISPR platform targets large cardiovascular markets, supported by blue-chip partnerships and prominent venture investors including Andreessen Horowitz.
Apnimed Inc. (APMD): Peeking at the IPO Prospectus of a Sleep-Related Biopharma
- Late-Stage biotech targeting OSA with AD109, an investigational oral therapy, has submitted an NDA following positive Phase 3 results in approximately 1,300 patients.
- Addresses an estimated 80 million U.S. adults with obstructive sleep apnea, offering a potential first oral pharmacologic treatment for a large underserved market.
- Backed by Morningside Ventures and Sectoral Asset Management, with over $200 million raised to support late-stage development and potential commercialization.
LC Capital Extends PC Partner Position; Rich Placement
- Over five sessions, directors and substantial shareholders filed 50 interests for 20 stocks, including acquisitions and disposals.
- Kopernik Global Investors increased its stake in Golden Agri-Resources to 7.07% through acquisitions, reflecting institutional conviction.
- HealthBank Holdings raised S$2.67 million through a share placement to finance new businesses and strategic investments.
Bears Build Into Earnings Season: Short Interest Spikes Across Small Caps
- Short sellers were active the week of July 13.
- Borrow costs exploded on several names, led by a leveraged ETF tracking Micron hitting 441% of float.
- Earnings season drove positioning on both sides – bears loaded up on some names while covering hard on others.
Scribe Therapeutics (SCTX) Targets $100 Million IPO
- Scribe Therapeutics (NASDAQ: SCTX) has filed for an initial public offering of 7.15 million shares priced between $13.00 and $15.00 per share, targeting gross proceeds of approximately $100.1 million at the midpoint of the range.
- At a midpoint price of $14.00, Scribe would debut with an implied market capitalization of approximately $226.5 million based on 16.18 million shares outstanding following the offering and concurrent private placement.
- The IPO is being led by Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
